Cargando…

Uveal Metastasis: Clinical Features and Survival Outcome of 2214 Tumors in 1111 Patients Based on Primary Tumor Origin

PURPOSE: The purpose of this study is to evaluate patients with uveal metastasis based on primary tumor site. METHODS: Retrospective analysis from Wills Eye Hospital, Philadelphia, PA, USA, for uveal metastasis clinical features and outcomes based on the primary tumor site. RESULTS: There were 2214...

Descripción completa

Detalles Bibliográficos
Autores principales: Shields, Carol L., Welch, R. Joel, Malik, Kunal, Acaba-Berrocal, Luis A., Selzer, Evan B., Newman, Jennifer H., Mayro, Eileen L., Constantinescu, Alexandru B., Spencer, Meredith A., McGarrey, Mark P., Knapp, Austen N., Graf, Alexander E., Altman, Alex J., Considine, Sean P., Shields, Jerry A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071342/
https://www.ncbi.nlm.nih.gov/pubmed/30122853
http://dx.doi.org/10.4103/meajo.MEAJO_6_18
_version_ 1783343854716452864
author Shields, Carol L.
Welch, R. Joel
Malik, Kunal
Acaba-Berrocal, Luis A.
Selzer, Evan B.
Newman, Jennifer H.
Mayro, Eileen L.
Constantinescu, Alexandru B.
Spencer, Meredith A.
McGarrey, Mark P.
Knapp, Austen N.
Graf, Alexander E.
Altman, Alex J.
Considine, Sean P.
Shields, Jerry A.
author_facet Shields, Carol L.
Welch, R. Joel
Malik, Kunal
Acaba-Berrocal, Luis A.
Selzer, Evan B.
Newman, Jennifer H.
Mayro, Eileen L.
Constantinescu, Alexandru B.
Spencer, Meredith A.
McGarrey, Mark P.
Knapp, Austen N.
Graf, Alexander E.
Altman, Alex J.
Considine, Sean P.
Shields, Jerry A.
author_sort Shields, Carol L.
collection PubMed
description PURPOSE: The purpose of this study is to evaluate patients with uveal metastasis based on primary tumor site. METHODS: Retrospective analysis from Wills Eye Hospital, Philadelphia, PA, USA, for uveal metastasis clinical features and outcomes based on the primary tumor site. RESULTS: There were 2214 uveal metastases diagnosed in 1111 consecutive patients. The demographics included mean age of 60 years (median 61 years), Caucasian race (88%), and female gender (64%). The tumor was unilateral (82%) and primary site was established before uveal metastasis (67%). The primary tumor originated in the breast (37%), lung (26%), kidney (4%), gastrointestinal (GI) tract (4%), cutaneous melanoma (2%), lung carcinoid (2%), prostate (2%), thyroid (1%), pancreas (1%), other sites (3%), and unknown (16%). Comparative analysis of the 5 most common primary sites (breast, lung, kidney, GI tract, and cutaneous melanoma), revealed metastasis at mean age (57, 62, 66, 61, 59 years), as unilateral tumor (74%, 86%, 85%, 93%, 85%), with mean number of metastasis/eye (1.9, 1.7, 1.0, 1.1, 2.0), and in females (99%, 46%, 26%, 25%, 30%). Choroidal metastases measured mean base (9.3, 10.2, 9.1, 11.0, 7.3 mm), mean thickness (2.4, 3.6, 4.4, 4.0, 2.9 mm), and demonstrated predominant color yellow (94%, 91%, 56%, 97%, 36%). Of the 769 patients with documented follow-up, mean patient survival was poor (22.2, 11.5, 8.6, 12.4, 11.4 months) and Kaplan–Meier analysis revealed 3-year survival (33%, 19%, 0%, 14%, 21%) and 5-year survival (24%, 13%, 0%, 14%, 21%). The worst survival was found in patients with pancreatic metastasis (mean 4.2 months) and best survival with lung carcinoid (92% at 5 years). CONCLUSION: In a tertiary referral service, uveal metastasis originates from cancer in the breast, lung, kidney, GI tract, cutaneous melanoma, or others. Overall prognosis is poor with 5-year survival at 23% and worst survival with pancreatic metastasis whereas best survival with lung carcinoid metastasis.
format Online
Article
Text
id pubmed-6071342
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-60713422018-08-17 Uveal Metastasis: Clinical Features and Survival Outcome of 2214 Tumors in 1111 Patients Based on Primary Tumor Origin Shields, Carol L. Welch, R. Joel Malik, Kunal Acaba-Berrocal, Luis A. Selzer, Evan B. Newman, Jennifer H. Mayro, Eileen L. Constantinescu, Alexandru B. Spencer, Meredith A. McGarrey, Mark P. Knapp, Austen N. Graf, Alexander E. Altman, Alex J. Considine, Sean P. Shields, Jerry A. Middle East Afr J Ophthalmol Original Article PURPOSE: The purpose of this study is to evaluate patients with uveal metastasis based on primary tumor site. METHODS: Retrospective analysis from Wills Eye Hospital, Philadelphia, PA, USA, for uveal metastasis clinical features and outcomes based on the primary tumor site. RESULTS: There were 2214 uveal metastases diagnosed in 1111 consecutive patients. The demographics included mean age of 60 years (median 61 years), Caucasian race (88%), and female gender (64%). The tumor was unilateral (82%) and primary site was established before uveal metastasis (67%). The primary tumor originated in the breast (37%), lung (26%), kidney (4%), gastrointestinal (GI) tract (4%), cutaneous melanoma (2%), lung carcinoid (2%), prostate (2%), thyroid (1%), pancreas (1%), other sites (3%), and unknown (16%). Comparative analysis of the 5 most common primary sites (breast, lung, kidney, GI tract, and cutaneous melanoma), revealed metastasis at mean age (57, 62, 66, 61, 59 years), as unilateral tumor (74%, 86%, 85%, 93%, 85%), with mean number of metastasis/eye (1.9, 1.7, 1.0, 1.1, 2.0), and in females (99%, 46%, 26%, 25%, 30%). Choroidal metastases measured mean base (9.3, 10.2, 9.1, 11.0, 7.3 mm), mean thickness (2.4, 3.6, 4.4, 4.0, 2.9 mm), and demonstrated predominant color yellow (94%, 91%, 56%, 97%, 36%). Of the 769 patients with documented follow-up, mean patient survival was poor (22.2, 11.5, 8.6, 12.4, 11.4 months) and Kaplan–Meier analysis revealed 3-year survival (33%, 19%, 0%, 14%, 21%) and 5-year survival (24%, 13%, 0%, 14%, 21%). The worst survival was found in patients with pancreatic metastasis (mean 4.2 months) and best survival with lung carcinoid (92% at 5 years). CONCLUSION: In a tertiary referral service, uveal metastasis originates from cancer in the breast, lung, kidney, GI tract, cutaneous melanoma, or others. Overall prognosis is poor with 5-year survival at 23% and worst survival with pancreatic metastasis whereas best survival with lung carcinoid metastasis. Medknow Publications & Media Pvt Ltd 2018 /pmc/articles/PMC6071342/ /pubmed/30122853 http://dx.doi.org/10.4103/meajo.MEAJO_6_18 Text en Copyright: © 2018 Middle East African Journal of Ophthalmology http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Shields, Carol L.
Welch, R. Joel
Malik, Kunal
Acaba-Berrocal, Luis A.
Selzer, Evan B.
Newman, Jennifer H.
Mayro, Eileen L.
Constantinescu, Alexandru B.
Spencer, Meredith A.
McGarrey, Mark P.
Knapp, Austen N.
Graf, Alexander E.
Altman, Alex J.
Considine, Sean P.
Shields, Jerry A.
Uveal Metastasis: Clinical Features and Survival Outcome of 2214 Tumors in 1111 Patients Based on Primary Tumor Origin
title Uveal Metastasis: Clinical Features and Survival Outcome of 2214 Tumors in 1111 Patients Based on Primary Tumor Origin
title_full Uveal Metastasis: Clinical Features and Survival Outcome of 2214 Tumors in 1111 Patients Based on Primary Tumor Origin
title_fullStr Uveal Metastasis: Clinical Features and Survival Outcome of 2214 Tumors in 1111 Patients Based on Primary Tumor Origin
title_full_unstemmed Uveal Metastasis: Clinical Features and Survival Outcome of 2214 Tumors in 1111 Patients Based on Primary Tumor Origin
title_short Uveal Metastasis: Clinical Features and Survival Outcome of 2214 Tumors in 1111 Patients Based on Primary Tumor Origin
title_sort uveal metastasis: clinical features and survival outcome of 2214 tumors in 1111 patients based on primary tumor origin
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6071342/
https://www.ncbi.nlm.nih.gov/pubmed/30122853
http://dx.doi.org/10.4103/meajo.MEAJO_6_18
work_keys_str_mv AT shieldscaroll uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin
AT welchrjoel uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin
AT malikkunal uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin
AT acababerrocalluisa uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin
AT selzerevanb uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin
AT newmanjenniferh uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin
AT mayroeileenl uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin
AT constantinescualexandrub uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin
AT spencermereditha uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin
AT mcgarreymarkp uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin
AT knappaustenn uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin
AT grafalexandere uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin
AT altmanalexj uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin
AT considineseanp uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin
AT shieldsjerrya uvealmetastasisclinicalfeaturesandsurvivaloutcomeof2214tumorsin1111patientsbasedonprimarytumororigin